In August, Pfizer halted production of its single-dose vial version of naloxone because of a manufacturing issue it’s been working with the FDA to solve.
Drug experts estimate the shortage will mean about 1 million fewer naloxone doses, which could lead to as many as 18,000 avoidable overdose deaths.
Pfizer expects the shortage to continue through February, according to the report.